NYLIM
TBPH icon

New York Life Investment Management’s Theravance Biopharma TBPH Stock Holding History

New York Life Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,709
Closed -$116K – 270
2015
Q1 		$116K Hold
6,709
– – 0.01% 221
2014
Q4 		$100K Buy
+6,709
New +$117K 0.01% 242

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return

New York Life Investment Management's TBPH Position: Q2 2015 in Review

New York Life Investment Management sold out of Theravance Biopharma (TBPH) in Q2 2015, closing a stake of 6,709 shares — an estimated $116K sold.

New York Life Investment Management first reported a position in TBPH in Q4 2014 and held it in 2 quarters. The position peaked at $116K in Q1 2015. 91 funds tracked by Wall St. Rank hold TBPH as of Q2 2015.

  • New York Life Investment Management reported no remaining Theravance Biopharma position as of Q2 2015 after selling out during the quarter.
  • New York Life Investment Management sold 6,709 Theravance Biopharma shares in Q2 2015, an estimated $116K.
  • New York Life Investment Management first reported a position in Theravance Biopharma in Q4 2014 and held it in 2 quarters.
  • New York Life Investment Management's Theravance Biopharma position peaked at $116K in Q1 2015.
  • 91 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2015.

Based on New York Life Investment Management's 13F filing for Q2 2015, filed 13 Aug 2015.